Despite a growing appreciation for TP53 mutations that confer novel functions that could worsen AML (e.g., gain of function (GOF) mutations), there was no difference in survival whether a patient had TP53 mutations classified as disruptive or non-disruptive [35]. Here, TP53 is linked to acute myeloid leukemia.